Gilead Sciences: Lymphoma, B-Cell, Marginal Zone trials
The registry lists 11 Lymphoma, B-Cell, Marginal Zone studies with Gilead Sciences as lead sponsor. 0 are open to participants now and 6 have results posted.
Phase 1 5Phase 2 5Phase 3 4(a study in two phases counts in both)
Studies
Open to participants first, then studies with results posted, then the rest; newest registration first within each.
- A Study of Axicabtagene Ciloleucel in Participants With Relapsed/Refractory Indolent Non-Hodgkin LymphomaCompletedNCT03105336Phase 2Results posted
- Study to Evaluate Safety, Tolerability, and Pharmacokinetics of Idelalisib in Japanese Participants With Relapsed or Refractory Indolent B-Cell Non-Hodgkin Lymphomas (iNHL) or Chronic Lymphocytic Leukemia (CLL)CompletedNCT02242045Phase 1Results posted
- Efficacy and Safety of Idelalisib (GS-1101) in Combination With Bendamustine and Rituximab for Previously Treated Indolent Non-Hodgkin LymphomasTerminatedNCT01732926Phase 3Results posted
- Efficacy and Safety of Idelalisib (GS-1101) in Combination With Rituximab for Previously Treated Indolent Non-Hodgkin LymphomasTerminatedNCT01732913Phase 3Results posted
- Safety and Efficacy Study of Idelalisib (GS-1101, CAL-101) in Patients With Previously Treated Low-grade LymphomaCompletedNCT01306643Phase 1/2Results posted
- Efficacy and Safety Study of Idelalisib in Participants With Indolent B-Cell Non-Hodgkin LymphomasCompletedNCT01282424Phase 2Results posted
- Safety, Pharmacodynamics, Pharmacokinetics, and Efficacy of GS-9901 in Adults With Relapsed or Refractory Follicular Lymphoma, Marginal Zone Lymphoma, Chronic Lymphocytic Leukemia, or Small Lymphocytic LymphomaTerminatedNCT02258555Phase 1
- Phase I Dose Escalation Study of IMMU-114 in Relapsed or Refractory NHL and CLLTerminatedNCT01728207Phase 1
- Safety Study of Different Doses of hA20 (Veltuzumab) in CD20+ Non-Hodgkin's LymphomaCompletedNCT00596804Phase 1/2
- Monoclonal Antibodies in Detecting Residual Disease in Patients Who Have Been Treated for Non-Hodgkin's LymphomaStatus unknownNCT00003338Phase 2/3
- Radiolabeled Monoclonal Antibody in the Detection and Staging of Patients With Non-Hodgkin's LymphomaStatus unknownNCT00003337Phase 3